JP2005509000A5 - - Google Patents

Download PDF

Info

Publication number
JP2005509000A5
JP2005509000A5 JP2003543568A JP2003543568A JP2005509000A5 JP 2005509000 A5 JP2005509000 A5 JP 2005509000A5 JP 2003543568 A JP2003543568 A JP 2003543568A JP 2003543568 A JP2003543568 A JP 2003543568A JP 2005509000 A5 JP2005509000 A5 JP 2005509000A5
Authority
JP
Japan
Prior art keywords
composition
liposome
agent
lyophilizing
vesicle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2003543568A
Other languages
English (en)
Japanese (ja)
Other versions
JP4555569B2 (ja
JP2005509000A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2002/001726 external-priority patent/WO2003041681A2/en
Publication of JP2005509000A publication Critical patent/JP2005509000A/ja
Publication of JP2005509000A5 publication Critical patent/JP2005509000A5/ja
Application granted granted Critical
Publication of JP4555569B2 publication Critical patent/JP4555569B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2003543568A 2001-11-13 2002-11-13 増強された血中安定性を有する脂質キャリア組成物 Expired - Lifetime JP4555569B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33124801P 2001-11-13 2001-11-13
US39427102P 2002-07-09 2002-07-09
PCT/CA2002/001726 WO2003041681A2 (en) 2001-11-13 2002-11-13 Lipid carrier compositions with enhanced blood stability

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2009242896A Division JP2010018632A (ja) 2001-11-13 2009-10-21 増強された血中安定性を有する脂質キャリア組成物

Publications (3)

Publication Number Publication Date
JP2005509000A JP2005509000A (ja) 2005-04-07
JP2005509000A5 true JP2005509000A5 (https=) 2005-12-15
JP4555569B2 JP4555569B2 (ja) 2010-10-06

Family

ID=26987658

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2003543568A Expired - Lifetime JP4555569B2 (ja) 2001-11-13 2002-11-13 増強された血中安定性を有する脂質キャリア組成物
JP2009242896A Withdrawn JP2010018632A (ja) 2001-11-13 2009-10-21 増強された血中安定性を有する脂質キャリア組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2009242896A Withdrawn JP2010018632A (ja) 2001-11-13 2009-10-21 増強された血中安定性を有する脂質キャリア組成物

Country Status (8)

Country Link
US (3) US20050118250A1 (https=)
EP (1) EP1443900B1 (https=)
JP (2) JP4555569B2 (https=)
AU (1) AU2002340669A1 (https=)
CA (1) CA2467064C (https=)
ES (1) ES2387886T3 (https=)
PT (1) PT1443900E (https=)
WO (1) WO2003041681A2 (https=)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2467064C (en) * 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
JP4874547B2 (ja) * 2002-11-26 2012-02-15 ギリアード サイエンシーズ， インコーポレイテッド 勾配によるリポソームへの薬物充填方法
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
EP1643972A4 (en) * 2003-06-27 2010-01-20 Smithkline Beecham Corp STABILIZED LIPOSOMAL TOPOTECAN COMPOSITION AND METHOD
CA2928387A1 (en) 2004-05-03 2005-11-17 Merrimack Pharmaceuticals, Inc. Drug delivery liposomes containing anionic polyols or anionic sugars
JP4885715B2 (ja) * 2004-06-01 2012-02-29 テルモ株式会社 イリノテカン製剤
JP4715133B2 (ja) * 2004-08-26 2011-07-06 コニカミノルタエムジー株式会社 抗腫瘍リポソーム製剤およびその製造方法
US20090285878A1 (en) * 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
US20070154403A1 (en) * 2006-01-05 2007-07-05 Thomas Skold Oral, Pulmonary and Transmucosal Delivery Composition
AU2007235463B2 (en) * 2006-03-30 2012-11-22 The Research Foundation Of State University Of New York Compositions of less immunogenic and long-circulating protein-lipid complexes
JP2009545621A (ja) * 2006-08-02 2009-12-24 ユナイテッド セラピューティクス コーポレーション ウィルス感染症のリポソーム処置
US20090196917A1 (en) * 2008-02-01 2009-08-06 University Of Kentucky Research Foundation Liposomal Formulations of Hydrophobic Lactone Drugs in the Presence of Metal Ions
US20090252785A1 (en) * 2008-03-26 2009-10-08 University Of Oxford Endoplasmic reticulum targeting liposomes
EP2123258A1 (en) 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomes for drug delivery
AR076634A1 (es) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc Composiciones y metodo para tratar desordenes del sistema nervioso central
KR20120059447A (ko) * 2009-03-27 2012-06-08 더 챈슬러 마스터즈 앤드 스칼라스 오브 더 유니버시티 오브 옥스포드 콜레스테롤 수준 저하 리포좀
ES2593027T3 (es) * 2009-03-30 2016-12-05 Eisai R&D Management Co., Ltd. Composición liposomal
EP2415464B1 (en) 2009-03-30 2017-05-10 Eisai R&D Management Co., Ltd. Method for producing liposome composition
DK177532B1 (en) * 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
DK177529B1 (en) 2009-10-23 2013-09-08 Bio Bedst Aps Liposomes with improved storage stability
PT2508170E (pt) * 2009-12-03 2015-10-16 Shanghai Hengrui Pharm Co Ltd Lipossoma de irinotecano ou o seu cloridrato e seu método de preparação
JP2013529638A (ja) * 2010-06-19 2013-07-22 ウェスタン ユニバーシティ オブ ヘルス サイエンス Ｐｅｇ化リポソーム封入糖ペプチド抗生物質の新規製剤
ITMI20111271A1 (it) * 2011-07-08 2013-01-09 Giuseppe Milani Prodotto alimentare del tipo da conservare e consumare refrigerato o congelato
EP3572071A1 (en) * 2011-10-21 2019-11-27 Jazz Pharmaceuticals Research LLC Lyophilized liposomes
PL2861214T3 (pl) * 2012-06-14 2021-02-08 Universität Bern Liposomy przystosowane do leczenia zakażeń bakteryjnych
US9801874B2 (en) 2012-11-20 2017-10-31 Spectrum Pharmaceuticals Method for the preparation of liposome encapsulated vincristine for therapeutic use
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
RS61273B1 (sr) * 2014-04-30 2021-01-29 Fujifilm Corp Lipozomska kompozicija i postupak za njeno dobijanje
TWI678213B (zh) 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
MX382522B (es) 2015-10-16 2025-03-13 Ipsen Biopharm Ltd Composiciones farmaceuticas estabilizantes de camptotecina.
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
US12029724B2 (en) 2016-04-28 2024-07-09 Eisai R&D Management Co., Ltd. Method for inhibiting tumor growth
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
AU2018266111B2 (en) 2017-05-08 2024-11-07 Flagship Pioneering Innovations V, Inc. Compositions for facilitating membrane fusion and uses thereof
US10459751B2 (en) * 2017-06-30 2019-10-29 ATI Technologies ULC. Varying firmware for virtualized device
CN111629715A (zh) 2018-01-18 2020-09-04 弗莱德哈钦森癌症研究中心 通过调节细胞活化状态改变体内免疫细胞的炎症状态
US11590079B2 (en) * 2018-01-18 2023-02-28 EndoProtech, Inc. Treating microvascular dysfunction
MX2021001820A (es) * 2018-09-14 2021-04-28 Pharmosa Biopharm Inc Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos.
EP3856198A4 (en) 2018-09-25 2022-06-22 Celator Pharmaceuticals, Inc. Low-intensity treatment of hematological disorders
EP4137527A1 (en) 2018-12-04 2023-02-22 TIEN, Der-Yang Stereocomplexes for the delivery of anti-cancer agents
CA3119037A1 (en) 2018-12-11 2020-06-18 Disruption Labs Inc. Compositions for the delivery of therapeutic agents and methods of use and making thereof
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11083705B2 (en) 2019-07-26 2021-08-10 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
US12036204B2 (en) 2019-07-26 2024-07-16 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumor
JP2023535790A (ja) 2020-07-28 2023-08-21 ジャズ ファーマシューティカルズ アイルランド リミテッド 縮合二環式ｒａｆ阻害薬及びその使用方法
WO2022023450A1 (en) 2020-07-28 2022-02-03 Jazz Pharmaceuticals Ireland Limited Chiral synthesis of fused bicyclic raf inhibitors
US11980636B2 (en) 2020-11-18 2024-05-14 Jazz Pharmaceuticals Ireland Limited Treatment of hematological disorders
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2024209267A2 (en) 2023-04-03 2024-10-10 Jazz Pharmaceuticals Ireland Limited Modulators of nanoparticle uptake
TW202543582A (zh) * 2024-02-29 2025-11-16 美商葛里柯麥公司 脂質體調配物及其使用及製備方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
DE3686025T2 (de) * 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
JPH0617309B2 (ja) * 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
US4927571A (en) * 1987-05-18 1990-05-22 Liposome Technology, Inc. Preparation of injectable doxorubicin/liposome suspension
AU598958B2 (en) * 1987-11-12 1990-07-05 Vestar, Inc. Improved amphotericin b liposome preparation
US4915951A (en) * 1987-12-03 1990-04-10 California Institute Of Technology Cryoprotective reagent
WO1990003795A1 (en) * 1988-10-05 1990-04-19 Vestar, Inc. Method of making liposomes with improved stability during drying
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
US5225212A (en) * 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
IS1685B (is) * 1990-12-11 1998-02-24 Bracco International B.V. Aðferð við að búa til fitukúlur (liposomes) sem eru gæddar auknum hæfileika til að draga í sig og halda í sér aðskotaefnum
GB9111611D0 (en) 1991-05-30 1991-07-24 Sandoz Ltd Liposomes
US5648532A (en) * 1993-06-03 1997-07-15 The Regents Of The University Of California Compositions for boron neutron capture therapy and methods thereof
US5415869A (en) * 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
PT101422B (pt) 1993-12-06 1997-06-30 Ineti Inst Biotec Q F E Tecnol Formulacoes lipossomicas contendo vidarabina e/ou derivados, com indice terapeutico elevado e processo para a sua preparacao
US6139871A (en) * 1995-07-26 2000-10-31 The University Of British Columbia Liposome compositions and methods for the treatment of atherosclerosis
JPH07316041A (ja) 1994-03-28 1995-12-05 Dai Ichi Seiyaku Co Ltd 保持容量を向上させたリポソーム
CN1148336A (zh) 1994-03-28 1997-04-23 第一制药株式会社 增大包封量的脂质体
AU714043B2 (en) * 1994-10-03 1999-12-16 Infectio Recherche Inc. Liposome-formulations for treatment of viral diseases
CA2263455C (en) * 1996-08-23 2002-10-29 Sequus Pharmaceuticals, Inc. Liposomes containing a cisplatin compound
US6120800A (en) * 1997-09-25 2000-09-19 Nexstar Pharmaceuticals, Inc. Vinca-alkaloid vesicles with enhanced efficacy and tumor targeting properties
AU756109B2 (en) 1997-12-04 2003-01-02 Hadasit Medical Research Services & Development Company Ltd Methods for antitumor therapy
JPH11171772A (ja) 1997-12-11 1999-06-29 Sankyo Co Ltd 抗腫瘍薬のリポソーム化製剤
AU4196099A (en) 1998-05-21 1999-12-06 Isis Pharmaceuticals, Inc. Long-circulating liposomal compositions
US6200598B1 (en) * 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6270806B1 (en) 1999-03-03 2001-08-07 Elan Pharma International Limited Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
JP2001026544A (ja) 1999-05-11 2001-01-30 Sankyo Co Ltd 脂溶性抗腫瘍薬のリポソーム製剤
DE60014093T2 (de) * 1999-07-16 2005-02-03 Alza Corp., Mountain View Liposomzusammensetzung mit Schutz vor Gefrier-/Aufbau-Schaden
JP2001302496A (ja) 2000-04-14 2001-10-31 Takeda Chem Ind Ltd リポソーム製剤
JP4540287B2 (ja) * 2001-03-02 2010-09-08 日油株式会社 ポリアルキレンオキシド修飾リン脂質の製造方法
DE60208454T2 (de) * 2001-03-02 2006-09-07 Nof Corp. Polyalkylenoxid-modifizierte Phospholipide und Verfahren zu ihrer Herstellung
CA2467064C (en) * 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability

Similar Documents

Publication Publication Date Title
JP2005509000A5 (https=)
CA2467064A1 (en) Lipid carrier compositions with enhanced blood stability
JP4883840B2 (ja) プロトン化／酸性化核酸の肺輸送
US5851536A (en) Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
ES2520028T3 (es) Formulaciones inhaladas de doble acción, que proporcionan un perfil de liberación tanto inmediata como sostenida
ES2285712T3 (es) Medicamento para la terapia y profilaxis de varias enfermedades relacionadas con nf-kappa b.
JP2007533670A5 (https=)
US4877619A (en) Liposomal vesicles for intraperitoneal administration of therapeutic agents
US6180114B1 (en) Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
ES2285860T3 (es) Sistema de aporte de farmacos proteinicos usando mimeticos de membrana.
JP2010530846A (ja) 高温で安定なペプチド製剤
JP2008505902A5 (https=)
ES2394458T3 (es) Metilación de vectores plasmídicos
FI3173073T3 (fi) Liposomeja lääkkeen antamiseen
JP2001522783A5 (https=)
IL139636A (en) (s)-2-ethoxy-3-[4-(2{4-methanesulfonyloxyphenyl} ethoxy) phenyl] propanoic acid, process for its preparation, pharmaceutical composition containing it and use thereof in the manufacture of medicament for the prophylaxis or treatment of clinical conditions associated with insulin resistance
CY1119580T1 (el) Νεα φαρμακα σκευασματα χρησιμα στη θεραπευτικη αγωγη της αϋπνιας
RU2005115956A (ru) Способ лечения инсулинорезистентности, диабета взрослых и метаболического синдрома х
JP2002503714A5 (https=)
CN116531340A (zh) mRNA脂质纳米颗粒的冻干制剂及其制备方法
CN117157049A (zh) Atp合酶抑制剂-化妆品和治疗用途
JP2006510606A5 (https=)
ES2317938T3 (es) Uso de analogos de acidos grasos para el tratamiento y/o prevencion de enfermedades proliferativas de la piel.
JPH0334920A (ja) リポソームに結合及至組合わされた生物活性化合物及びそれを含有する医薬
JP2004517808A5 (https=)